glp-1 small molecule agonist glp-1_analogs [TUSOM A novel approach to exploit

Description

Am J Ophthalmol 2025;274:24-31.ArticlePubMed 100

[DOI] [PubMed] [Google Scholar] 91.Alba M, Yee J, Frustaci ME, Samtani MN & Fleck P Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study

Argentina and Colombia apply strict prior-authorization hurdles that lengthen initiation and depress uptake, effectively confining large segments of the Latin America GLP-1 agonists market to private payers

Keep a simple log of redeemed deals to avoid missing out on staggered rewards or overlapping timelines

GLP-1 also affects non-hunger related (hedonic) feeding by targeting brain areas involved in reward, motivation and addiction, such as the VTA, NAcc, lateral septum [701,741,744,745], and PVT [704]